In this study, we present a cost-effectiveness analysis comparison of amivantamab–lazertinib combination therapy and lazertinib monotherapy against standard osimertinib treatment in advanced NSCLC patients with EGFR exon 20 insertion mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.